期刊文献+

基质金属蛋白酶及其抑制物在先心病继发肺动脉高压中的作用 被引量:1

下载PDF
导出
摘要 目的探讨先天性心脏病(以下简称先心病)患儿血清中的基质金属蛋白酶(MMP-1,MMP-2)、组织金属蛋白酶抑制物(TIMP-1)水平,及其与先天性心脏病并肺动脉高压(PAH)的关系。方法将71例在向右分流型先天性心脏病患者,按肺动脉收缩压(SPAP)水平分为四组:非PAH组和PAH组,PAH组又分为轻度、中度、重度PAH组;其中,24例接受手术治疗。21例同龄正常体检儿童作为对照组。用酶联免疫吸附法(ELISA)检测血清MMP-1、MMP-2和TIMP-1含量。结果 PAH组MMP1、MMP-2、TIMP-1与对照组、非PAH组相比均显著增高;在轻度PAH、中度PAH、重度PAH组MMP-1、MMP-2、TIMP-1无显著性差异。24例手术治疗患者的MMP-1、MMP-2与术前相比显著降低,差异有统计学意义。结论先心病患儿血清中均存在MMP-1、MMP-2水平增高,其参与了肺血管重构的全过程;手术治疗,可有效降低肺血管重构因子MMP-1、MMP-2和TIMP-1水平,其机制是手术阻断了先心病异常的血流动力学这一肺血管重构的始动因子。
出处 《中国医学创新》 CAS 2011年第22期26-27,共2页 Medical Innovation of China
  • 相关文献

参考文献5

  • 1顾虹.肺动脉高压病因学最新研究进展[J].临床儿科杂志,2009,27(5):406-409. 被引量:6
  • 2秦玉明,周爱卿,贲晓明,沈捷,梁瑛,李奋.间质胶原酶在实验性肺高压肺血管重建中表达的动态改变[J].上海医学,2001,24(11):667-670. 被引量:4
  • 3Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Anti - remode- ling effects of iloprost and the dual - selective phosphodiesterase 3/4inhibitor tolafentrine in chronic experimental pulmonary hyperten- sion. Circ Res, 2004,94 ( 8 ) : l101 - 1108.
  • 4Southgate KM, Davis M, Booth RFG, et al. involvement of extracellar matrix - degrading Metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J ,2002,288:93 - 99.
  • 5Kolpakov V, Rekhter MD, Cordon D, et al. Effect of mechanical forces on growth and matrix protein synthesis in the in vitro pulmonary arter- y. Cite Res,1995,77(4) :823 -83l.

二级参考文献34

  • 1Nichols WC,Koller DL,Slovis B,et al.Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32[J].Nat Genet,1997,15(3):277-281.
  • 2Morse JH,Jones AC,Barst RT,et al.Mapping of familial primary pulmonary hypertension on locus (PPH1) to chromosome 2q31-q32[J].Circulation,1997,95(12):2603-2606.
  • 3Deng Z,Morse JH,Slager SL,et al.Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-Ⅱ gene[J].Am J Hum Genet,2000,67(3):737-744.
  • 4Lane KB,Machado RD,Pauciulo MW,et al.Heterozygous germline mutations in BMPR2,encoding a TGF-beta receptor,cause familial primary pulmonary hypertension.The International PPH Consortium[J].Nat Genet,2000,26(1):81-84.
  • 5Machado RD,Pauciulo MW,Thomson JR,et al.BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension[J].Am J Hum Genet,2001,68(1):92-102.
  • 6Thomson JR,Machado RD,Pauciulo MW,et al.Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-Ⅱ,a receptor member of the TGF-beta family[J].J Med Genet,2000,37 (10):741-745.
  • 7中西宣文:肺高血庄症における遗伝子異常[J].血管医学,2007-2008,8:237-243.
  • 8Morse J,Barst R,Horn E,et al.Pulmonary hypertension in scleroderma spectrum of disease:lack of bone morphogenetic protein receptor 2 mutations[J].J Rheumatol,2002,29(11):2379-2381.
  • 9Roberts KE,McElroy JJ,Wong WP,et al.BMPR2 mutations in pulmonary hypertension with congenital heart disease[J].Eur Respir J,2004,24(3):371-374.
  • 10Humbert M,Deng Z,Simonneau G,et al.BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives[J].Eur Respir J,2002,20 (3):518-523.

共引文献8

同被引文献9

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部